HomeCompareRPTX vs QSR

RPTX vs QSR: Dividend Comparison 2026

RPTX yields 75.47% · QSR yields 3.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RPTX wins by $1.33M in total portfolio value
10 years
RPTX
RPTX
● Live price
75.47%
Share price
$2.65
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.35M
Annual income
$375,142.22
Full RPTX calculator →
QSR
QSR
● Live price
3.40%
Share price
$73.76
Annual div
$2.51
5Y div CAGR
-0.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.7K
Annual income
$387.88
Full QSR calculator →

Portfolio growth — RPTX vs QSR

📍 RPTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRPTXQSR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RPTX + QSR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RPTX pays
QSR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RPTX
Annual income on $10K today (after 15% tax)
$6,415.09/yr
After 10yr DRIP, annual income (after tax)
$318,870.89/yr
QSR
Annual income on $10K today (after 15% tax)
$289.25/yr
After 10yr DRIP, annual income (after tax)
$329.70/yr
At 15% tax rate, RPTX beats the other by $318,541.19/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RPTX + QSR for your $10,000?

RPTX: 50%QSR: 50%
100% QSR50/50100% RPTX
Portfolio after 10yr
$688.8K
Annual income
$187,765.05/yr
Blended yield
27.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on QSR right now

RPTX
Analyst Ratings
7
Buy
2
Hold
Consensus: Buy
Price Target
$3.00
+13.2% upside vs current
Range: $3.00 — $3.00
Altman Z
-0.1
Piotroski
3/9
QSR
Analyst Ratings
27
Buy
15
Hold
2
Sell
Consensus: Buy
Price Target
$81.57
+10.6% upside vs current
Range: $71.00 — $90.00
Altman Z
1.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RPTX buys
0
QSR buys
0
No recent congressional trades found for RPTX or QSR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRPTXQSR
Forward yield75.47%3.40%
Annual dividend / share$2.00$2.51
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-0.8%
Portfolio after 10y$1.35M$24.7K
Annual income after 10y$375,142.22$387.88
Total dividends collected$1.17M$3.7K
Payment frequencyquarterlyquarterly
SectorStockStock
Analyst consensusBuyBuy
Analyst price target$3.00$81.57

Year-by-year: RPTX vs QSR ($10,000, DRIP)

YearRPTX PortfolioRPTX Income/yrQSR PortfolioQSR Income/yrGap
1← crossover$18,247$7,547.17$11,038$337.57+$7.2KRPTX
2$32,395$12,870.51$12,156$345.43+$20.2KRPTX
3$56,017$21,354.74$13,359$352.69+$42.7KRPTX
4$94,449$34,510.84$14,654$359.36+$79.8KRPTX
5$155,442$54,381.15$16,045$365.45+$139.4KRPTX
6$249,967$83,643.80$17,539$370.97+$232.4KRPTX
7$393,173$125,708.24$19,143$375.96+$374.0KRPTX
8$605,486$184,791.09$20,863$380.42+$584.6KRPTX
9$913,831$265,960.98$22,708$384.39+$891.1KRPTX
10$1,352,941$375,142.22$24,685$387.88+$1.33MRPTX

RPTX vs QSR: Complete Analysis 2026

RPTXStock

Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.

Full RPTX Calculator →

QSRStock

Restaurant Brands International Inc. operates as quick service restaurant company in Canada and internationally. It operates through four segments: Tim Hortons (TH), Burger King (BK), Popeyes Louisiana Kitchen (PLK), and Firehouse Subs (FHS). The company owns and franchises TH chain of donut/coffee/tea restaurants that offer blend coffee, tea, and espresso-based hot and cold specialty drinks; and fresh baked goods, including donuts, Timbits, bagels, muffins, cookies and pastries, grilled paninis, classic sandwiches, wraps, soups, and others. It is also involved in owning and franchising BK, a fast food hamburger restaurant chain, which offers flame-grilled hamburgers, chicken and other specialty sandwiches, french fries, soft drinks, and other food items; and PLK quick service restaurants that provide Louisiana style fried chicken, chicken tenders, fried shrimp and other seafood, red beans and rice, and other regional items. In addition, the company owns and franchises FHS restaurants quick service restaurants that offer subs, soft drinks, and local specialties. As of February 15, 2022, the company had approximately 29,000 restaurants in 100 countries under the Tim Hortons, Burger King, Popeyes, And Firehouse Subs brands. Restaurant Brands International Inc. was founded in 1954 and is headquartered in Toronto, Canada.

Full QSR Calculator →
📬

Get this RPTX vs QSR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RPTX vs SCHDRPTX vs JEPIRPTX vs ORPTX vs KORPTX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.